Abstract
Background: Metabolic disorders comprise a set of different disorders varying from epidemic diseases such as diabetes mellitus to inborn metabolic orphan diseases such as phenylketonuria. Despite considerable evidence showing the importance of the computational methods in discovery and development of new pharmaceuticals, there are no systematic reviews outlining how they are utilized in the field of metabolic disorders. This review aims to discuss the necessity of the development of web-based tools and databases by integration of available information for solving Big Data problems in network pharmacology of metabolic disorders.
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. The quality of retrieved papers was appraised using standard tools.
Results: The alterations in metabolic pathways cause various cardiovascular, hematological, neurological, gastrointestinal, immune disorders and cancer. In this regard, informatics, Big Data and modeling techniques aid in the design of novel therapeutic agents for metabolic diseases by addressing various Big Data problems in the network polypharmacology (drugs/pharmaceutical agents, proteins, genes, diseases, bioassays, ADMET and metabolic pathways), identification of privileged scaffolds, developing new diagnostic biomarkers, understanding the pathophysiology of disease and progress in personalized medicine.
Conclusion: The recent advances of developing pharmaceutical agents for various metabolic disorders by considering their pathogenesis, mechanisms of action, therapeutic and adverse effects have been summarized. We have highlighted the role of computational techniques, drug repurposing, and network-based polypharmacological approaches in the identification of new/existing medicines with improved drug-likeness properties for the rare metabolic disorders.
Keywords: Big data and modeling, drug repurposing, informatics, metabolic disorders, network polypharmacology, orphan diseases.
Current Medicinal Chemistry
Title:Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective
Volume: 25 Issue: 39
Author(s): Sridhara Janardhan, Varvara Dubovskaja, Alexey Lagunin, Batchu Venkateswara Rao, Garikapati Narahari Sastry*Vladimir Poroikov*
Affiliation:
- Centre for Molecular Modeling, CSIR-Indian Institute of Chemical Technology, Hyderabad-500 007,India
- Institute of Biomedical Chemistry, Moscow, 119121,Russian Federation
Keywords: Big data and modeling, drug repurposing, informatics, metabolic disorders, network polypharmacology, orphan diseases.
Abstract: Background: Metabolic disorders comprise a set of different disorders varying from epidemic diseases such as diabetes mellitus to inborn metabolic orphan diseases such as phenylketonuria. Despite considerable evidence showing the importance of the computational methods in discovery and development of new pharmaceuticals, there are no systematic reviews outlining how they are utilized in the field of metabolic disorders. This review aims to discuss the necessity of the development of web-based tools and databases by integration of available information for solving Big Data problems in network pharmacology of metabolic disorders.
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. The quality of retrieved papers was appraised using standard tools.
Results: The alterations in metabolic pathways cause various cardiovascular, hematological, neurological, gastrointestinal, immune disorders and cancer. In this regard, informatics, Big Data and modeling techniques aid in the design of novel therapeutic agents for metabolic diseases by addressing various Big Data problems in the network polypharmacology (drugs/pharmaceutical agents, proteins, genes, diseases, bioassays, ADMET and metabolic pathways), identification of privileged scaffolds, developing new diagnostic biomarkers, understanding the pathophysiology of disease and progress in personalized medicine.
Conclusion: The recent advances of developing pharmaceutical agents for various metabolic disorders by considering their pathogenesis, mechanisms of action, therapeutic and adverse effects have been summarized. We have highlighted the role of computational techniques, drug repurposing, and network-based polypharmacological approaches in the identification of new/existing medicines with improved drug-likeness properties for the rare metabolic disorders.
Export Options
About this article
Cite this article as:
Janardhan Sridhara, Dubovskaja Varvara, Lagunin Alexey, Rao Venkateswara Batchu, Sastry Narahari Garikapati*, Poroikov Vladimir*, Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective, Current Medicinal Chemistry 2018; 25 (39) . https://dx.doi.org/10.2174/0929867324666171002120647
DOI https://dx.doi.org/10.2174/0929867324666171002120647 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Co-morbidity of Diabetes Mellitus and Orodental Diseases in Nigeria
Current Diabetes Reviews Recent Patents on Oral Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Association between ALDH2 Gene Polymorphism and Late-onset Alzheimer Disease: An Up-to-date Meta-analysis
Current Alzheimer Research Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
Current Clinical Pharmacology Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology Carotid Intima Media-thickness and Genes Involved in Lipid Metabolism in Diabetic Patients using Statins – a Pathway Toward Personalized Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design Effect of Fasting Ramadan in Diabetes Control Status - Application of Extensive Diabetes Education, Serum Creatinine with HbA1c Statistical ANOVA and Regression Models to Prevent Hypoglycemia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Deciphering the Inactivation of Human Pancreatic α-Amylase, an Antidiabetic Target, by Bisdemethoxycurcumin, a Small Molecule Inhibitor, Isolated from Curcuma longa
The Natural Products Journal Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Multiple Drug Resistance Associated with Function of ABC-Transporters in Diabetes Mellitus: Molecular Mechanism and Clinical Relevance
Infectious Disorders - Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery